Highly pure phospholipids based brain docosahexaenoic acid transporters

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 2, 2010, Pages 135-146

  Chen, Su ^a  

^a Chainon Biotechnology Inc   (United States)

Author keywords

Age dependent cholinergic neurodegeneration; Alzheimer's disease; Choline acetyltransferase; Dementia; Docosahexaenoic acid; Ether phospholipids; Lipid metabolism; Lysophosphatidylcholine; Lysophosphatidylethanolamine; P75 neurotrophin receptor; Phosphatidyl monomethylethanoamine; Phosphatidylcholine; Phosphatidylethanolamine; Phosphatidylserine; Phospholipids

Indexed keywords

AMINOPHOSPHOLIPID; DOCOSAHEXAENOIC ACID; LYSOPHOSPHOLIPID; NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLMONOMETHYLETHANOLAME; PHOSPHATIDYLSERINE; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL SURVIVAL; CHOLINERGIC NERVE CELL; CORPUS STRIATUM; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG METABOLISM; DRUG STRUCTURE; FOREBRAIN; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE FLUIDITY; NERVE MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BRAIN; DOCOSAHEXAENOIC ACIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEURONS; PHOSPHOLIPIDS;

EID: 77953820016     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910791213185     Document Type: Article

References (83)

1. Baskin DS, Browning JL, Pirozzolo FJ. Brain choline acetyltrans- ferase and mental function in Alzheimer's disease. Arch Neurol 1999; 56(9): 1121-3.
2. Cynthia B, Bazinet R, Ma D. Experimental models and nechanism underlying the protective effects of n-3 polyunsaturated fatty acids in Alzhermer's disease. J Nutr Biochem 2009; 20(1): 1-10.
3. Beckermann B, Beneke M, Seitz I. Comparative bioavailability of eicosapentaenoic acid and docosahexaenoic acid from triacyl-glycerides, free fatty acid and ethyl esters in volunteers. Arzneimittelforschung 1990; 40(6): 700-4.
4. Ponroy, Y. Dietetic phospholipid compositions and use thereof as a dietary supplement. US5869530 (1999).
5. Katz, R., Tomoaia-Cotisel, M. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic. acid-conjugated polycationic carrier. US5716614 (1998).
6. Shulman, A., Rassan, Z., Gai, B., Dror, D., Pelled, D.P., Orly, F., Zohar, B.-O., Tael, R. Glycerophospholipids for the improvement of cognitive functions. US20090074857 (2009).
7. Etcheberrigaray, R., Daniel, A. Methods for Alzheimer's disease treatment and cognitive enhancement. US6825229 (2004).
8. McCleary, E.L. Composition and method for treating impaired or deteriorating neurological function. US6964969 (2005).
9. Shapiro, H. Methods of treating neurological diseases and etiolo- gically related symptomology using carbonyl trapping agents in combination with previously known medicaments. US5668117 (1997).
10. Hageman, R.J.J., De Wilde, M.C., Kamphuis, P.J.G.H. Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition. WO2007073178 (2007).
11. Stoll, A., Severus, W. Omega-3 fatty acids and omega-3 phosphati- dylcholine in the treatment of bipolar disorder. WO97039759 (1997).
12. Shulman, A., Gai, B.D., Dori, P., Zohar, B-.O. Mimetic lipids and dietary supplements comprising the same. WO2005051091 (2005).
13. Dror, G.B., Platt, D., Farkash, O., Zuabi, R., Bar-on, Z., Shulman, A., Pelled, D., Richter, Y. Glycerophospholipids for the improvement of cognitive functions. US20090074857 (2009).
14. Shirai K, Barnhart RL, Jackson RL. Hydrolysis of human plasma high-density lipoprotein 2-phospholipids and triglycerides by hepatic lipase. Biochem Biophys Res Commun 1981; 100(2): 464-70.
15. Spector AA. Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci 2001; 16(2-3): 159-65.
16. Schaefer EJ, Vanina B, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer's disease: The Framingham Heart Study. Arch Neurol 2006; 63(11): 1545-50.
17. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer's diseases: OmegaAD study: A randomized double-blind trial. Arch Neurol 2006; 63(10): 1402-8.
18. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves congnitive dysfunction. Neurosci Res 2006; 56(2): 159-64.
19. Jorissen BL, Brouns F, Van Boxtel MP, Riedel WJ. Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci 2002; 5(5): 337-43.
20. Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and diseases. Prostaglandings Leukot Essent Fatty Acid 2008; 79(3): 153-56.
21. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: Results of a multicenter study. Psychopharmacol Bull 1988; 24(1): 130-34.
22. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effect of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41(5): 644-9.
23. Crook T, Petrie W, Wells C, Massari DC. Effect of phos-phatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992; 28(1): 61-6.
24. Pepeu G, Pepeu MI, Amaducci L. A review of phosphatidylserine pharmaceutical and clinical effects: Is phosphatidylserine a drug for aging brain? Pharmacol Res 1996; 33(2): 73-80.
25. Chen S, Li KW. Comparison of molecular species of various transphosphatidylated soy-phosphatidylserine with bovine cortex PS by mass spectrometry. Chem Phys Lipids 2008; 152(1): 46-54.
26. Hosokawa K, Shimatani T, Kanada T, Inoue Y. Conversion to docosahexaenoic acid-containing phosphatidylserine from squid skin lecithin by phospholipase D-mediated transphosphatidylation. J Agric Food Chem 2000; 48(10): 4550-7.
27. Chen S, Li KW. Mass spectrometric identification of molecular species of phosphatidylcholine and lysophosphatidylcholine extracted from shark liver. J Agric Food Chem 2007; 55(23): 9670-7.
28. Moriguchi T, Salem N. Effect of phosphatidylserine DHA (PS-DHA) on the learning ability of N-3 fatty acid deficient mice. The 7th ISSFAL, Queensland, Australia, CS 6.2, July (2006).
29. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol 2008; 9(2): 112-24.
30. Lemmon MA. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 2008; 9(2): 99-111.
31. Fedorova A, Hussein N, Baumann MH, Di Martino C, Salem N Jr. An n-3 fatty acid deficiency impairs rat spatial learning in the Barnes Maze. Behav Neurosci 2009; 123(1): 196-205.
32. Kim HY, Akbar M, Kim KY. Inhibition of neuronal apoptosis by polyunsaturated fatty acids. J Mol Neurosci 2001; 16(2-3): 223-7.
33. Favrelere S, Stadelmann-Ingrand S, Huguet F, De Javel D, Piriou A, Tallineau C, et al. Age-related changes in ethanolamine phospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol Aging 2001; 21(5): 653-60.
34. McGahon BM, Martin DS, Horrobin DF, Lynch MA. Age-related changes in synaptic function: Analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 1999; 94(1): 305-14.
35. Glomset JA. Role of docosahexaenoic acid in neuronal plasma membrane. Sci STKE 2006; 2006(321): 6.
36. Salem N, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36(9): 945-59.
37. Kim HY. Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem 2007; 282(26): 18661-5.
38. Champeol-Potokar G, Chaumontet C, Guesnet P, Lavialle M, Denis I. Docosahexaenoic acid (22: 6n-3) enrichment of membrane phospholipids increases gap junction coupling capacity in cultured astrocytes. Eur J Neurosci 2006; 24(11): 3084-90.
39. Farooqui A, Ong WY, Horrocks LA. Biochemical aspects of neuro-degeneration in human brain: Involvement of neural membrane phospholipids and phospholipase A2. Neurochem Res 2004; 29(11): 1961-77.
40. Terry A, Buccafusco B. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306(6): 821-35.
41. Auld DS, Hennicken F, Quirion R, Nerve growth factor induces prolonged acetylcholine release from cultured basal forebrain neurons: Differentiation between neuromodulatory and neuro-trophinc influences. J Neurosci 2001; 21(10): 3375-82.
42. Sims A, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40(2): 503-9.
43. Mufson EL, Shuang Y, John D, Cochran EJ, Leurgans S, Wuu J, et al. Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Compar Neurol 2002; 443(2): 136-53.
44. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, et al. Failed retrograder transport of NGF in mouse model of down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001; 98(18): 10439-44.
45. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61(1): 41-62.
46. Kim HY, Bigelow J, Kevala JH. Substrate preference in phos-phatidylserine biosynthesis for docosahexaenoic acid containing species. Biochemistry 2004; 43(4): 1030-6.
47. Kim HY, Akbar M, Lau A. Effects of docosahexaenoic acid on neuronal apoptosis. Lipids 2003; 38(4): 453-67.
48. Lim A, Salem N. An extraordinary degree of structural specificity is required in neural phospholipids for optimal brain function: n-6 docosapentaenoic acid substitution for docosahexaenoic acid leads to a loss in spatial task performance. J Neurochem 2007; 95(3): 848-57.
49. Hamilton J, Grener R, Salem N, Kim HY. n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids 2000; 35(8): 863-9.
50. Guo M, Stockert L, Akbar M, Kim HY. Neuronal specific increase of phosphatidylserine by docosahexaenoic acid. J Mol Neurosci 2007; 33(1): 67-73.
51. Plourde M, Fortier M, Vandal J, Tremblay-Mercier J, Freemantle E, Bégin M, et al. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prostaglandins Leukot Essent Fatty Acids 2007; 77(5): 301-8.
52. Kim HY, Akbar M, Lau A, Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22: 6n-3). J Biol Chem 2000; 275(45): 35215-23.
53. Lagarde M, Bernoud N, Brossard N, Lemaitre-Delaunay D, Thiès F,Croset M, et al. Lysophosphatidylcholine as preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci 2001; 16(2-3): 201-4.
54. Thies F, Delachambre MC, Bentejac M, Lagarde M, Lecerf J. Unsaturated fatty acids esterified in 2-acyl-1-lysophosphatidyl-choline bound to albumin are more efficiently taken up by the young rat brain than the non-esterified form. J Neurochem 1992; 59(3): 1110-16.
55. Lagarde M. Docosahexaenoic acid: Neutrient and precursor of bioactive lipids. Eur J Lipid Sci Technol 2008; 110(8): 673-78.
56. Chen S, Subbaiah PV. Phospholipid and fatty acid specificity of endothelial lipase: Potential role of the enzyme in the delivery of docosahexaenoic Acid (DHA) to tissues. Biochim Biophys Acta 2007; 171(10): 1319-28.
57. Ramos GC, Fernandes D, Charão CT, Souza DG, Teixeira MM, Assreuy J. Apoptotic mimicry: Phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo. Br J Pharmacol 2007; 151(6): 844-50.
58. Kingsley M. Effects of phosphatidylserine supplementation on exercising humans. Sports Med 2006; 36(8): 657-69.
59. Hossain Z, Kurihara H, Hosokawa M, Takahash K. Docosa-hexaenoic acid and eicosapentaenoic acid-enriched phospha-tidylcholine liposomes enhance the permeability, transportation and uptake of phospholipids in Caco-2 cells. Mol Cell Biochem 2006; 285(1-2): 155-62.
60. Galli C, Sirtori CR, Mosconi C, Medini L, Gianfranceschi G, Vaccarino V, et al. Prolonged retention of doubly labeled phosphatidylcholine in human plasma and erythrocytes after oral administration. Lipids 1992; 27(12): 1005-15.
61. Lemaitre-Delaunay A, Pachiaudi C, Laville M, Pousin J, Armstrong M, Lagarde M. Blood compartmental metabolism of doco-sahexaenoic acid (DHA) in humans after ingestion of a single dose of [13C] DHA in phosphatidylcholine. J Lipid Res 1999; 40(10): 1867-74.
62. Arnesjo B, Nilsson A, Barrowman J, Borgström B. Intestinal digestion and absorption of cholesterol and lecithin in the Human. Scand J Gastroenterol 1969; 4(8): 653-65.
63. Delong CJ, Shen YJ, Thomas MJ, Cui Z. Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and PE methylatoin pathway. J Biol Chem 1999; 274(42): 29683-8.
64. Schuiki I, Daum G. Phosphatidylserine decarboxylases, key enzymes of lipid metabolism. IUBMB Life 2009; 61(2): 151-62.
65. Palatini P, Viola G, Bigon E, Menegus AM, Bruni A. Pharmacokinetic characterization of phosphatidylserine liposome in the rat. Br J Pharmacol 1991; 102(2): 345-51.
66. Gauster M, Rechberger G, Sovic A, Hörl G, Steyrer E, Sattler W, et al. Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein Phosphatidylcholine. J Lipid Res 2005; 46(7): 1517-25.
67. Paltauf F. Ether lipids in biomembranes. Chem Phys Lipids 1994; 74(2): 101-27.
68. Martin-Nizard F, Meresse S, Cecchelli R, Fruchart JC, Delbart C. Interactions of high-density lipoprotein 3 with brain capillary endothelial cells. Biochim Biophys Acta 1989; 1005(3): 201-8.
69. Balazs Z, Panzenboeck U, Hammer A, Andrea S, Oswald Q, Ernst M, et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated a-tocopherol by an in vitro blood-brain barrier model. J Neurochem 2004; 89(4): 939-50.
70. Illingworth DR, Portman OW. The uptake and metabolism of plasma lysoPC in vivo by the brain of squirrel monkeys. Biochem J 1972; 130(2): 557-67.
71. Stone SJ, Vance JE. Phosphatidylserine-synthase-1 and -2 are located to mitochondria-associated membranes. J Biol Chem 2000; 275(44): 34534-40.
72. Igarashi M, DeMar CJ Jr, Ma K, Chang L, Bell JM, Rapoport SI, et al. Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J Lipid Res 2007; 48(5): 1150-58.
73. Brenna S, Salem N Jr, Sinclair AJ, Cunnane SC. Alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009; 80(2-3): 85-97.
74. Chen, S., Chen, R. Composition and method for promoting survival of aged basal forebrain cholinergic neuron leading to provention and tratment of age-related neurodegenerative disorder. US200912497583 (2009).
75. Kubo K, Saito M, Tadokoro T, Maekawa A. Preferential incorporation of docosahexaenoic acid into nonphosphorus lipids and phosphatidylethanolamine protects rats from dietary DHA-stimulated lipid peroxidation. J Nutr 2000; 130(7): 1749-59.
76. Merkl A, Lands WA. Metabolism of glycerolipids. J Biol Chem 1963; 238(8): 905-10.
77. Masuzawa Y, Sugiura T, Sprecher H, Waku K. Selective acyl transfer in the reacylation of brain glycerophospholipids. Comparison of three acylation systems for 1-al-alk-1'-enylglycero-3-phosphoethanolamine, 1-acylglycero-3-phosphocholine and 1-acylglycero-3-phosphocholine in rat brain microsomes. Biochim Biophys Acta 1989; 1005(1): 1-12.
78. Chen, S., Kwong, H. Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species. US20090131368 (2009).
79. Rosa AO, Rapoport SI. Intracellular- and extracellular-derived Ca(2+) influence phospholipase A2-mediated fatty acid release from brain phospholipids. Biochim Biophys Acta 2009; 1791(8): 697-705.
80. Ojima A, Nakagawa Y, Sugiura T, Masuzawa Y, Waku K. Selective transacylation of 1-O-alkylglycerophosphoethanolamine by docosahexaenoate and arachidonate in rat brain microsomes. J Neurochem 1987; 48(5): 1403-10.
81. Bazan NG. Synaptic lipid signaling: Significance of polyun-saturated fatty acids and platelet-activiting factor. J Lipid Res 2003; 44(12): 2221-33.
82. Masoudi R, Ioannou MS, Coughlin MD, Pagadala P, Neet KE, Clewes O, et al. Biological activity of never growth factor precursor is dependent upon relative levels of its receptor. J Biol Chem 2009; 284(27): 18424-33.
83. Abstracts, International Conference on Alzheimer's disease, July 2009; Vienna, Austria [http://www.alz.org/icad/2010_release_071209_1am_b.asp].